Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder

Inclusion Criteria:

- Male and female subjects between 18 and 55 years of age, inclusive, with a diagnosis
of schizophrenia or schizoaffective disorder as defined by DSM-IV-TR criteria.

- Body mass index of 19 to 35 kg/m2.

Exclusion Criteria:

- Females who are pregnant or lactating. A negative serum pregnancy test must be
confirmed prior to the first dose of trial medication for all female subjects.

- Subjects presenting with a first episode of schizophrenia or schizoaffective disorder
based on the clinical judgment of the investigator.

- Subjects who have received continuous medication therapy to treat schizophrenia or
schizoaffective disorder for less than 6 months prior to washout.

- Subjects with schizophrenia or schizoaffective disorder that are considered
resistant/refractory to antipsychotic treatment by history, who have a history of
failure to clozapine, or who are responsive only to clozapine treatment.

- Subjects with a current DSM-IV-TR Axis I diagnosis other than schizophrenia or
schizoaffective disorder.

- Hospitalization for an exacerbation of schizophrenia or schizoaffective disorder
within 3 months prior to randomization.

- Subjects who have a history of or who have evidence of other medical and/or
neurological conditions that would expose them to an undue risk of a significant AE
or interfere with assessments of safety or efficacy during the course of the trial.

- Subjects with a history of neuroleptic malignant syndrome.

- Subjects with a history of seizure disorder.

- Subjects who meet DSM-IV-TR criteria for substance dependence within 6 months prior
to randomization.